Graft Versus Host Disease
|Recruiting||Chronic Graft Versus Host Disease (cGVHD)||Phase I||
Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder. This randomized phase I trial is studying how well cyclosporine eye drops work in preventing graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Age greater than or equal to 18 years at time of enrollment
- Day 80-120 after first allogeneic stem cell transplant for hematologic malignancies or -marrow failure disorder at time of study enrollment
- Signed informed consent
- Willing to adhere to protocol requirements
- History of non-compliance
- Diagnosis of ocular GVHD at time of study enrollment
- Documented dry eye prior to onset of stem cell transplant
- Significant non- GVHD ocular problems that precludes participation in study
- Life expectancy of lesser than 6 months at time of enrollment (viz. grade 4 acute GVHD, florid progression or relapse of underlying disease)
- History of documented ocular infections prior to stem cell transplant or during transplant (i.e. history of herpetic keratitis)
- Females who are pregnant or breastfeeding
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.